C91.41 Hairy cell leukemia, in remission

Name of the Condition

• Hairy cell leukemia, in remission
• ICD-10 Code: C91.41

Summary

Hairy cell leukemia in remission is a hematologic condition where abnormal B lymphocytes with hair-like projections are no longer detectable or clinically active following treatment. This state indicates a response to therapy, with resolution of cytopenias (low blood cell counts) and reduced bone marrow infiltration. Remission may be partial or complete, and ongoing monitoring is typically required to detect potential relapse.

Causes

The exact cause of hairy cell leukemia is not fully understood, but it involves genetic mutations in B lymphocytes that disrupt normal cell regulation. Contributing factors may include environmental exposures or alterations in immune system function, though specific triggers remain unclear. Achieving remission reflects successful treatment response, not a change in the underlying genetic drivers of the disease.

Risk Factors

• Increasing age (most common in adults over 50)
• Male gender (slight predominance)
• Family history of hematologic malignancies (less clearly established)
• Prior treatment response (e.g., complete remission status)

Symptoms

• Absence of active disease symptoms (e.g., fatigue, infections, bruising)
• Normalized blood cell counts (if complete remission)
• No palpable spleen enlargement
• Asymptomatic status during routine follow-up

Diagnosis

Diagnosis of remission requires clinical and laboratory confirmation, including blood tests to assess cell counts, bone marrow evaluation to rule out residual disease, and potentially imaging studies. Documentation must demonstrate the absence of active leukemia signs, such as abnormal lymphocytes or cytopenias, consistent with treatment response.

Treatment Options

Treatment for hairy cell leukemia typically involves targeted therapies (e.g., purine analogs, immunotherapy) to induce remission. Once achieved, maintenance strategies may include observation, periodic monitoring, or additional therapy to sustain response. Treatment plans are individualized based on prior response and risk of relapse.

Prognosis and Follow-Up

Prognosis in remission is generally favorable, with many patients experiencing long-term disease control. Follow-up involves regular blood work, bone marrow assessments, and clinical evaluations to detect relapse early. The duration of remission varies, and some patients may require retreatment over time.

Complications

• Risk of relapse (return of active disease)
• Potential for treatment-related side effects (e.g., infections, cytopenias)
• Long-term monitoring requirements
• Psychological impact of ongoing surveillance

Lifestyle & Prevention

• Maintain regular medical follow-up as advised
• Practice infection prevention (e.g., hygiene, vaccinations)
• Report new symptoms promptly
• Avoid known environmental risk factors (e.g., unnecessary chemical exposures)

When to Seek Professional Help

Seek care if new symptoms (e.g., fatigue, fever, bruising) or signs of relapse (e.g., abnormal blood counts) occur. Immediate attention is needed for severe symptoms like uncontrolled bleeding or high fever.

Tips for Medical Coders

Document the presence of remission clearly in clinical records, including treatment response and absence of active disease. Code C91.41 is specific to hairy cell leukemia in remission; ensure documentation supports this status without ambiguity. Verify that remission is not confused with active disease or treatment failure.